What is Quantum Biopharma Ltd.'s earnings per share (EPS)?

Quantum Biopharma Ltd. (QNTM) reported diluted earnings per share of -$8.20 for fiscal year 2025. This represents a 37.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Quantum Biopharma Ltd. (QNTM) Financials

QNTM

FY2025 annual

Revenue Not reported for FY2025

Net Income Not reported for FY2025

EPS (Diluted) -$8.20 +37.5% YoY

Operating Cash Flow -$8.2M -19.8% YoY

Market Cap $20.0M as of Oct 17, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m no net income reported

Price / Book 3.9x on $5.1M equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Dec 31, 2025 Reported Mar 26, 2026 Currency USD FYE December

Newest figures come from the 20-F for FY2025, filed Mar 26, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the QNTM SEC filings page.

This page shows Quantum Biopharma Ltd. (QNTM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial health score not available

Quantum Biopharma Ltd. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

EPS (Diluted)

-$0.71

YoY+65.5%

QoQ+43.2%

Quantum Biopharma Ltd. earned -$0.71 per diluted share (EPS) in Q4 2025. This represents an increase of 65.5% from the same quarter a year earlier. Against the prior quarter it is up 43.2%.

Revenue

Not reported for Q4 2025.

EBITDA

Not reported for Q4 2025.

Net Income

Not reported for Q4 2025.

Cash & Balance Sheet

Cash & Debt

$1.9M

YoY-68.2%

QoQ+327.3%

Quantum Biopharma Ltd. held $1.9M in cash against $1.3M in long-term debt as of Q4 2025.

Free Cash Flow

Not reported for Q4 2025.

Dividends Per Share

Not reported for Q4 2025.

Shares Outstanding

Not reported for Q4 2025.

Margins & Returns

None of these metrics is reported for Q4 2025.

Capital Allocation

None of these metrics is reported for Q4 2025.

QNTM Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

QNTM quarterly income statement

Metric	FY2520-F	FY2420-F	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Interest Expense	$158K+1591.8%	$9K-61.5%	$24K-61.7%	$63K-8.6%	$69K-70.5%	$236K+51.7%	$155K	N/A
Net Income	N/A	N/A	N/A	-$23.6M+33.1%	-$35.3M-11.0%	-$31.8M+18.7%	-$39.1M	N/A
EPS (Basic)	-$8.20+37.5%	-$13.12+56.2%	-$29.93-4237.7%	-$0.69+28.9%	-$0.97+58.9%	-$2.36+51.1%	-$4.83	N/A
EPS (Diluted)	-$8.20+37.5%	-$13.12	-$29.93-4237.7%	-$0.69+28.9%	-$0.97	-$2.36	N/A	N/A
Diluted Shares (Avg)	N/A	1M	609,056+2.2%	595,883-98.3%	35M	12M	7M+19.5%	6M

Metric	Q4'2520-F	Q3'256-K	Q2'2510-Q	Q1'2510-Q	Q4'2420-F	Q3'246-K	Q2'2410-Q	Q1'2410-Q
Interest Expense	N/A	$92K+782.9%	$117K+1299.6%	$22K+78.6%	N/A	$10K+2829.2%	$8K	$12K
Net Income	N/A	-$4.7M-18.2%	-$9.8M-191.3%	-$8.7M-317.9%	N/A	-$4.0M-255.0%	-$3.4M	-$2.1M
EPS (Basic)	-$0.71+65.5%	-$1.25+71.4%	-$3.23-3937.5%	-$3.53-2.9%	-$2.06	-$4.37	-$0.08	-$3.43
EPS (Diluted)	-$0.71+65.5%	-$1.25	-$3.23	-$3.53	-$2.06	-$4.37	-$0.08	-$3.43
Diluted Shares (Avg)	N/A	N/A	N/A	N/A	N/A	917,848	42M	N/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Income Tax.

QNTM Balance Sheet

QNTM quarterly balance sheet

Metric	FY2520-F	FY2420-F	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Total Assets	$11.2M-34.8%	$17.1M-2.0%	$17.5M-54.5%	$38.4M-39.0%	$63.0M+50.0%	$42.0M-2.9%	$43.2M+8.9%	$39.7M
Current Assets	$6.5M-46.2%	$12.1M+8.7%	$11.1M-37.9%	$17.9M-61.1%	$45.9M+71.0%	$26.9M+213.9%	$8.6M-49.6%	$17.0M
Cash & Equivalents	$1.9M-68.2%	$6.0M+117.5%	$2.8M-83.8%	$17.0M-51.8%	$35.3M+101.2%	$17.5M+193.7%	$6.0M-62.5%	$15.9M
Inventory	$52K-55.5%	$117K	$0	N/A	N/A	$0-100.0%	$709K	$0
Accounts Receivable	N/A	N/A	N/A	$374K-25.3%	$501K+210.5%	$161K-89.6%	$1.6M+108.9%	$746K
Total Liabilities	$6.1M-9.3%	$6.7M+46.3%	$4.6M-42.0%	$7.9M-10.9%	$8.8M+56.1%	$5.7M-18.5%	$6.9M+429.0%	$1.3M
Current Liabilities	$6.1M-9.3%	$6.7M+46.3%	$4.6M-41.7%	$7.8M-10.0%	$8.7M+55.9%	$5.6M-18.3%	$6.8M+420.6%	$1.3M
Non-Current Liabilities	$0	$0	$0-100.0%	$38K-71.0%	$131K+65.6%	$79K-28.3%	$110K	$0
Long-Term Debt	$1.3M+110.1%	$619K	$0-100.0%	$38K-71.0%	$131K+65.6%	$79K-28.3%	$110K	$0
Total Equity	$5.1M-51.1%	$10.4M-19.1%	$12.9M-57.7%	$30.5M-43.6%	$54.1M+49.1%	$36.3M+0.1%	$36.3M-5.5%	$38.4M
Retained Earnings	-$198.3M-15.2%	-$172.1M-9.0%	-$157.9M-9.5%	-$144.2M-14.3%	-$126.2M-38.8%	-$90.9M-53.8%	-$59.1M-196.2%	-$19.9M

Metric	Q4'2520-F	Q3'256-K	Q2'2510-Q	Q1'2510-Q	Q4'2420-F	Q3'246-K	Q2'2410-Q	Q1'2410-Q
Total Assets	$11.2M-34.8%	$14.2M-25.6%	$15.3M+0.3%	$14.9M	$17.1M-2.0%	$19.0M	$15.2M	N/A
Current Assets	$6.5M-46.2%	$9.3M-32.5%	$10.3M+3.2%	$9.9M	$12.1M+8.7%	$13.8M	$10.0M	N/A
Cash & Equivalents	$1.9M-68.2%	$446K-85.7%	$1.5M-54.7%	$3.5M+164.5%	$6.0M+117.5%	$3.1M	$3.3M	$1.3M
Inventory	$52K-55.5%	$78K	$77K	$94K	$117K	N/A	N/A	N/A
Total Liabilities	$6.1M-9.3%	$6.6M+80.6%	$13.2M+162.6%	$10.3M	$6.7M+46.3%	$3.7M	$5.0M	N/A
Current Liabilities	$6.1M-9.3%	$6.6M	$13.2M+162.6%	$10.3M	$6.7M+46.3%	N/A	$5.0M	N/A
Non-Current Liabilities	$0	$0	$0	$0	$0	N/A	$0	N/A
Long-Term Debt	$1.3M+110.1%	$2.0M	$1.9M	$1.1M	$619K	N/A	N/A	N/A
Total Equity	$5.1M-51.1%	$7.5M-51.1%	$2.0M-79.9%	$4.5M-60.7%	$10.4M-19.1%	$15.3M+4.1%	$10.2M	$11.5M
Retained Earnings	-$198.3M-15.2%	-$195.3M-17.1%	-$189.9M-16.6%	-$180.7M	-$172.1M-9.0%	-$166.8M	-$162.9M	N/A

Not reported in any period shown, so not listed: Short-Term Investments, Accounts Receivable, Long-Term Investments, Goodwill.

QNTM Cash Flow Statement

QNTM quarterly cash flow statement

Metric	FY2520-F	FY2420-F	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Operating Cash Flow	-$8.2M-19.8%	-$6.9M+36.5%	-$10.8M+61.8%	-$28.3M-36.6%	-$20.7M-8.4%	-$19.1M-39.5%	-$13.7M	N/A
Depreciation & Amortization	$546K+11.3%	$491K-80.4%	$2.5M-44.7%	$4.5M+12.1%	$4.0M+3.7%	$3.9M+100.7%	$1.9M	N/A
Capital Expenditures	N/A	$0	$0-100.0%	$114K	$0	$0	N/A	N/A
Free Cash Flow	N/A	-$6.9M+36.5%	-$10.8M+61.9%	-$28.4M-37.1%	-$20.7M-8.4%	-$19.1M	N/A	N/A
Investing Cash Flow	-$2.0M-29.9%	-$1.5M-457.7%	-$270K-102.2%	$12.1M+4407.4%	$269K-95.9%	$6.5M+2921.3%	-$231K	N/A
Financing Cash Flow	$6.1M-47.5%	$11.6M+471.6%	-$3.1M-51.1%	-$2.1M-105.4%	$38.2M+58.1%	$24.2M+502.6%	$4.0M	N/A

Metric	Q4'2520-F	Q3'256-K	Q2'2510-Q	Q1'2510-Q	Q4'2420-F	Q3'246-K	Q2'2410-Q	Q1'2410-Q
Operating Cash Flow	-$306K+63.4%	-$1.7M+50.3%	-$1.9M-221.4%	-$4.3M-115.9%	-$836K+1.9%	-$3.5M-102.1%	-$606K	-$2.0M
Depreciation & Amortization	$129K+14.7%	$145K+20.3%	$141K+3.3%	$130K+7.9%	$113K	$121K	$137K	$120K
Investing Cash Flow	$351K-71.8%	$408K+111.8%	-$1.4M-284.4%	-$1.4M-5998.5%	$1.2M	-$3.5M-1184.8%	$738K	-$22K
Financing Cash Flow	$1.4M-42.7%	$261K-96.1%	$1.3M-30.1%	$3.1M+451.0%	$2.5M+9885.2%	$6.7M+12400.7%	$1.8M	$569K

Not reported in any period shown, so not listed: Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

QNTM Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

QNTM quarterly financial ratios

Metric	FY2520-F	FY2420-F	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Return on Equity	N/A	N/A	N/A	-77.3%-12.1pp	-65.2%+22.4pp	-87.6%+20.3pp	-107.9%	N/A
Return on Assets	N/A	N/A	N/A	-61.5%-5.4pp	-56.0%+19.7pp	-75.8%+14.8pp	-90.5%	N/A
Current Ratio	1.07-0.7x	1.80-0.6x	2.43+0.1x	2.28-3.0x	5.28+0.5x	4.82+3.6x	1.25-11.7x	12.94
Debt-to-Equity	0.25+0.2x	0.06+0.1x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.00

Metric	Q4'2520-F	Q3'256-K	Q2'2510-Q	Q1'2510-Q	Q4'2420-F	Q3'246-K	Q2'2410-Q	Q1'2410-Q
Return on Equity	N/A	-63.2%-37.1pp	-477.1%-444.2pp	-193.0%-174.8pp	N/A	-26.2%-18.5pp	-32.9%	-18.2%
Return on Assets	N/A	-33.5%-12.4pp	-63.8%-41.9pp	-58.8%	N/A	-21.1%	-22.0%	N/A
Current Ratio	1.07-0.7x	1.41	0.78-1.2x	0.96	1.80-0.6x	N/A	1.99	N/A
Debt-to-Equity	0.25+0.2x	0.260.0x	0.95+0.5x	0.24	0.06+0.1x	0.24	0.49	N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Quantum Biopharma Ltd. QNTM	FY2025	N/A	N/A	N/A	$20.0M	—
Medicinova, Inc. MNOV	FY2025	$410K	$12.0M	N/A	$69.9M	—
ABVC BioPharma, Inc. ABVC	FY2025	$296K	-$7.9M	N/A	$24.5M	—
PMV Pharmaceuticals, Inc PMVP	FY2025	N/A	-$77.7M	N/A	$64.7M	—
Applied Therapeutics, Inc. APLT	FY2024	$455K	-$105.6M	N/A	$14.9M	—
Precision BioSciences, Inc. DTIL	FY2025	$34.3M	-$45.7M	N/A	$159.3M	49/100

Where Quantum Biopharma Ltd. Ranks

Frequently Asked Questions

How much debt does Quantum Biopharma Ltd. have?

As of fiscal year 2025, Quantum Biopharma Ltd. (QNTM) had $1.9M in cash and equivalents against $1.3M in long-term debt.

What is Quantum Biopharma Ltd.'s operating cash flow?

Quantum Biopharma Ltd. (QNTM) recorded an outflow of $8.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Quantum Biopharma Ltd.'s total assets?

Quantum Biopharma Ltd. (QNTM) had $11.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What is Quantum Biopharma Ltd.'s current ratio?

Quantum Biopharma Ltd. (QNTM) had a current ratio of 1.07 as of fiscal year 2025, which is considered adequate.

What is Quantum Biopharma Ltd.'s debt-to-equity ratio?

Quantum Biopharma Ltd. (QNTM) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Quantum Biopharma Ltd.'s P/E ratio?

Quantum Biopharma Ltd. (QNTM) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $20.0M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Quantum Biopharma Ltd.'s price-to-sales ratio?

Quantum Biopharma Ltd. (QNTM) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $20.0M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.